# Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

> **NCT00410553** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Recurrent Ovarian Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage III Ovarian Cancer AJCC v6 and v7
- Stage III Uterine Corpus Cancer AJCC v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Uterine Corpus Cancer AJCC v7

## Interventions

- **DRUG:** Eribulin Mesylate
- **DRUG:** Gemcitabine Hydrochloride

## Key facts

- **NCT ID:** NCT00410553
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-14
- **Primary completion:** 2012-10-24
- **Final completion:** 2012-10-24
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410553, "Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00410553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*